This circumstance may explain the more marked effect on PDA growth of blocking all CXCR4 inhibitory functions with the CXCR4 inhibitor AMD3100 (7) than of preventing only the formation of the CXCL12–KRT19 coating. Here, CXCL12 is linked to Patent ductus arteriosus.